FIELD: chemistry.
SUBSTANCE: invention relates to a novel compound of formula (I) or a pharmaceutically acceptable salt thereof, where X1 is a binding atom or bivalent linking component selected from a group consisting of -O-, -S-, -SO2-O- and SO2NZ10; -X2 is absent or is such that X1-X2-effector has a formula selected from a group consisting of structures (given below); each n and m independently denotes 0 or 1; p is 0, 1 or 2; X3 means oxygen or sulphur and, additionally, when m = 0, can be SO2-O or SO2NZ10; each Y1 is carbon or nitrogen, and each Y2 and Y3 are carbon, where, if Y1 means nitrogen, Z1 is absent; Y4 means an oxygen or carbon atom; -Y5- means or (i) a single bond, (ii) = CH-, where the double bond = b = CH- is bonded to Y4; each of Z1, Z2 and Z4 means hydrogen; Z3 is selected from a group consisting of C1-C6alkyl, C1-C6alkyloxy and halogen; Z5 is selected from a group consisting of hydrogen, C1-C6alkyl, C1-C6alkyloxy; or Z3 and Z4 together with atoms with which they are bonded, form aromatic 6-membered ring condensed with a compound residue, provided that at least one of Z1, Z2 and Z4 means hydrogen; Z6 is selected from a group consisting of hydrogen and C1-C6alkyl; Y6 means a carbon atom; each Z7 independently denotes hydrogen or C1-C6alkyl; each Z8 independently denotes hydrogen or C1-C6alkyl; each Z9 independently denotes oxygen or sulphur; Z10 means hydrogen or alkyl, for example, C1-4-alkyl; and the effector is a fragment which, when released from the compound of formula (I), provides a fluorophore selected from coumarins, resorurines, fluoresceins and rhodamines; or provides a cytotoxic agent selected from bis(haloethyl)phosphoramidates, cyclophosphamides, gemcitabine, cytarabine, 5-fluorouracil, 6-mercaptopurine, camptothecin, topotecan, and so forth.
EFFECT: compounds of formula (I) are intended for treating a proliferative condition characterized by cells expressing cytochrome P450.
15 cl, 3 tbl, 5 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METABOLICALLY STABLE CYP-EICOSANOID ANALOGUES FOR THE TREATMENT OF CARDIOLOGICAL DISEASES | 2016 |
|
RU2761438C2 |
| L-NUCLEOSIDES ELICITING ANTI-HBV OR ANTI-EBV ACTIVITY, METHOD OF INHIBITION OF HBV OR EBV INFECTION | 1995 |
|
RU2171809C2 |
| COMPOUNDS | 2008 |
|
RU2461559C2 |
| ANDROGEN RECEPTOR SELECTIVE DESTROYING (SARD) LIGANDS AND METHODS OF THEIR USE | 2017 |
|
RU2795431C2 |
| PHARMACEUTICAL COMBINATION OF ATYPICAL ANTIPSYCHOTIC AND NMDA MODULATOR FOR TREATMENT OF SCHIZOPHRENIA, BIPOLAR DISORDER, COGNITIVE DISORDER, AND CLINICAL DEPRESSION | 2016 |
|
RU2802972C2 |
| PRODRUG FORMING COMPOUNDS | 2014 |
|
RU2667942C2 |
| NEW CONDENSED ISOQUINOLINES AS LIGANDS FOR DOPAMINE RECEPTORS | 1996 |
|
RU2177001C2 |
| METHODS AND INTERMEDIATE COMPOUNDS FOR PREPARING IMATINIB, OPTIONALLY RADIOLABELLED | 2006 |
|
RU2440999C2 |
| AMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR APPLICATION METHODS | 2017 |
|
RU2759913C2 |
| P38 INHIBITORS AND APPLICATION METHODS | 2004 |
|
RU2357957C2 |
